Emerging viral pathogens present a critical threat to U.S. health and economy. Nipah (NiV) and Hendra (HeV) viruses are members of the newly defined Henipavirus genus of the Paramyxoviridae. Nipah virus (NiV) is an emergent paramyxovirus that causes fatal encephalitis in up to 74% of infected patients, and there is increasing evidence of human-to-human transmission. NiV and HeV are designated as BSL4 and priority pathogens in the NIAID Biodefense Research Agenda. NiV, in particular, could be a devastating agent of agrobioterrorism if used against the pig farming industry. Endothelial syncytia are a pathognomonic feature of NiV infections, and are mediated by the fusion (F) and attachment (G) envelope glycoproteins. We recently identified ephrinB2 as the NiV and HeV receptor, and the expression of ephrinb2 on endothelial cells and neurons largely explains the known cellular tropism of both NiV amd HeV. The identification of the NiV receptor has shed light on the pathobiology of NiV infection, and can spur the rational development of effective therapeutics. In particular, we have used our knowledge of NiV-receptor interactions and the Molecular Screening Shared Resource at UCLA to screen small molecule chemical libraries, and have obtained candidate small molecule antagonists that block NiV envelope interactions with its cognate receptor. In response to RFA-AI-05-019 (Co-operative Research Partnership for Biodefense), we have proposed a highly collaborative, inter-disciplinary, and trans-center research effort that will synergize the synthetic organic chemistry expertise of Dr. Michael Jung (co-PI), the virus-receptor interaction expertise of the Dr. Benhur Lee (PI), and the biodefense and BSL4 virological expertise of Dr. Ramon Flick (co-Pi at UTMB, Galveston), to develop a therapeutic against NiV. We propose the following Specific Aims that are geared towards the identification of a lead compound that can be developed into a therapeutic against NiV, and likely, HeV. They are: (1) To develop small molecule antagonists that block NiV and HeV entry, and (2) To assess the anti-viral efficacy of these small molecule entry inhibitors in live virus challenge experiments under BSL4 conditions.
Aim 1 exploits the infrastructure and inter-disciplinary expertise already present at UCLA to identify and optimize entry inhibitors of NiV, and Aim 2 makes use of the already sizable federal investment in the BSL4 facilities at UTMB, Galveston. Dr. Ramon Flick is the co-director of the BSL4 facility at UTMB, Galveston, and has already collaborated with the PI on NiV entry experiments. Public Health Relevance: Nipah and Hendra viruses are designated priority pathogens, are deadly, and can be devastating agents of bioterrorism and agroterrorism (devastation of the live-stock industry). The proposed studies, if successful, will lead to the development of effective anti-Nipah (and Hendra) therapeutics that can be used in response to an outbreak of these priority pathogens. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI070495-03
Application #
7479669
Study Section
Special Emphasis Panel (ZAI1-LR-M (M2))
Program Officer
Tseng, Christopher K
Project Start
2006-08-01
Project End
2010-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
3
Fiscal Year
2008
Total Cost
$715,954
Indirect Cost
Name
University of California Los Angeles
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Vigant, Frederic; Santos, Nuno C; Lee, Benhur (2015) Broad-spectrum antivirals against viral fusion. Nat Rev Microbiol 13:426-37
Hollmann, Axel; Gonçalves, Sónia; Augusto, Marcelo T et al. (2015) Effects of singlet oxygen generated by a broad-spectrum viral fusion inhibitor on membrane nanoarchitecture. Nanomedicine 11:1163-7
Vigant, Frederic; Hollmann, Axel; Lee, Jihye et al. (2014) The rigid amphipathic fusion inhibitor dUY11 acts through photosensitization of viruses. J Virol 88:1849-53
Vigant, Frederic; Lee, Jihye; Hollmann, Axel et al. (2013) A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog 9:e1003297
Pernet, Olivier; Wang, Yao E; Lee, Benhur (2012) Henipavirus receptor usage and tropism. Curr Top Microbiol Immunol 359:59-78
Vigant, Frederic; Lee, Benhur (2011) Hendra and nipah infection: pathology, models and potential therapies. Infect Disord Drug Targets 11:315-36
Lee, Benhur; Ataman, Zeynep Akyol (2011) Modes of paramyxovirus fusion: a Henipavirus perspective. Trends Microbiol 19:389-99
Lee, Benhur (2011) Containing the contagion: treating the virus that inspired the film. Sci Transl Med 3:105fs6
Aguilar, Hector C; Lee, Benhur (2011) Emerging paramyxoviruses: molecular mechanisms and antiviral strategies. Expert Rev Mol Med 13:e6
Wolf, Mike C; Freiberg, Alexander N; Zhang, Tinghu et al. (2010) A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A 107:3157-62

Showing the most recent 10 out of 19 publications